MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
shares of common stock,...
$238,530K
Proceeds from exercise of
stock options,...
$98K
Sales and maturities
of marketable...
$74,542K
Net cash provided by
financing activities
$238,628K
Net cash provided by
(used in) investing...
$8,154K
Effect of exchange rate
changes on cash, cash...
$213K
Canceled cashflow
$66,388K
Net increase
(decrease) in cash, cash...
$161,377K
Canceled cashflow
$85,618K
Stock-based compensation
expense
$4,298K
Prepaid expenses, other
current and non-current...
-$4,248K
Non-cash lease expense
$2,656K
Depreciation and
amortization expense
$1,277K
Deferred revenue
$1,085K
Accretion of debt discount
$865K
Accounts receivable
-$497K
Purchase of marketable
securities
$63,388K
Acquisition of intangible
asset
$3,000K
Net cash used in
operating activities
-$85,618K
Canceled cashflow
$14,926K
Net loss
-$79,199K
Change in fair value of
warrant liability
-$12,778K
Accounts payable
-$2,979K
Accrued expenses and
other long-term...
-$2,025K
Lease liabilities
-$1,740K
Inventory
$1,662K
Other
$161K
Back
Back
Cash Flow
source: myfinsight.com
X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc (XFOR)